Tenax Therapeutics's Financials - Craft

$8.9 M

Mkt cap, 25-Apr-2018

Net income (Q2, 2017)3 M

Cash, 30-Jun-20172.2 M

Revenue/Financials

Annual

USD	FY, 2014	FY, 2015	FY, 2016
Revenue	158.9 k	49.3 k
Revenue growth, %		(69%)	(100%)
Cost of goods sold
Gross profit
R&D expense			6.5 m
General and administrative expense			3.9 m
Operating expense total			10.4 m
EBIT	(16.6 m)	(14.8 m)	(52.7 m)
EBIT margin, %	(10452%)	(30063%)
Interest expense	2.2 m	49.1 k
Income tax expense
Net Income	(19.5 m)	(14.1 m)	(43.9 m)

Source: SEC Filings

Quarterly

USD	Q1, 2016	Q2, 2016	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017
R&D expense	1.7 m	2.5 m	3.9 m	3.4 m	3.2 m	2.1 m	1.2 m
General and administrative expense	1.4 m	1.2 m	1.8 m	1.2 m	1.3 m	1.4 m	1.8 m
Operating expense total	3.1 m	3.7 m	5.7 m	4.7 m	4.5 m	3.5 m	3 m
Interest expense	1.1 k	404
Net Income	3 m	3.5 m	5.4 m	4.6 m	4.3 m	3.3 m	3 m

Source: SEC Filings

Annual

USD	FY, 2014	FY, 2015	FY, 2016
Cash	58.3 m	7.9 m	10 m
Accounts Receivable	36.4 k	76.5 k	72.6 k
Current Assets	59 m	17.5 m	13.6 m
PP&E	124.4 k	50.3 k	19.1 k
Goodwill	11.3 m	11.3 m
Total Assets	93.4 m	82.9 m	23.3 m
Accounts Payable	411.1 k	1.2 m	727.6 k
Current Liabilities	2.6 m	4.5 m	6.2 m
Long-term debt	346.9 k	100.2 k
Total Debt	346.9 k	100.2 k
Total Liabilities			6.2 m
Additional Paid-in Capital	219.5 m	221.1 m	221.8 m
Retained Earnings	(136.6 m)	(150.7 m)	(204.7 m)
Total Equity	82.9 m	70.4 m	17.1 m
Debt to Equity Ratio	0 x	0 x
Debt to Assets Ratio	0 x	0 x
Financial Leverage	1.1 x	1.2 x	1.4 x

Quarterly

USD	Q1, 2016	Q2, 2016	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017
Cash	3.7 m	5.1 m	3.3 m	1.9 m	722.2 k	7 m	2.2 m
Accounts Receivable	98.6 k	86.3 k	49.3 k	24.6 k	72.6 k	24.6 k	24.6 k
Current Assets	21.6 m	21.9 m	16.1 m	10.2 m	7.7 m	12.8 m	9 m
PP&E	54.4 k	42.1 k	34 k	29 k	23.5 k	18.3 k	14.9 k
Goodwill	11.3 m	11.3 m	11.3 m	11.3 m	11.3 m
Total Assets	78.6 m	75.5 m	69.5 m	64.1 m	59.7 m	19.2 m	13.4 m
Accounts Payable	680.7 k	521.2 k	2.1 m	1.5 m	1.4 m	1.4 m	434.2 k
Current Liabilities	3.3 m	3.6 m	6.2 m	5.3 m	5.1 m	5 m	2.2 m
Long-term debt	48.4 k
Total Debt	48.4 k
Total Liabilities	11.2 m	11.5 m	14.2 m	13.2 m	13 m	5 m	2.2 m
Additional Paid-in Capital	221.1 m	221.2 m	221.4 m	221.5 m	221.7 m	222.1 m	222.2 m
Retained Earnings	(153.7 m)	(157.2 m)	(166.1 m)	(170.7 m)	(175 m)	(207.9 m)	(210.9 m)
Total Equity	67.4 m	63.9 m	55.3 m	50.9 m	46.7 m	14.1 m	11.3 m
Financial Leverage	1.2 x	1.2 x	1.3 x	1.3 x	1.3 x	1.4 x	1.2 x

Annual

USD	FY, 2014	FY, 2015	FY, 2016
Net Income	(19.5 m)	(14.1 m)	(10.1 m)
Depreciation and Amortization	150.5 k	148.1 k	31.2 k
Inventories
Cash From Operating Activities	(9.3 m)	(9.7 m)	(9 m)
Purchases of PP&E	(9.8 k)	(4.2 k)	(16.7 k)
Cash From Investing Activities	(147 k)	(40.9 m)	4.8 m
Cash From Financing Activities	66.9 m	280.6 k	(100.2 k)
Interest Paid			1.5 k

Quarterly

USD	Q1, 2016	Q2, 2016	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017
Net Income	(3 m)	(6.6 m)	(5.4 m)	(10 m)	(14.3 m)	(3.3 m)	6.3 m
Depreciation and Amortization	12.7 k	25 k	4.6 k	9.7 k	14.5 k	4 k	7.5 k
Cash From Operating Activities	(3.8 m)	(6.5 m)	(3.3 m)	(8.5 m)	(12.8 m)	(4 m)	(9.6 m)
Purchases of PP&E	(16.7 k)	(16.7 k)	(2.9 k)	(2.9 k)	(2.9 k)	(3.3 k)	(3.3 k)
Cash From Investing Activities	(380.9 k)	3.8 m	2.9 m	6.8 m	9.8 m	1.1 m	1.9 m
Cash From Financing Activities	(51.8 k)	(100.2 k)
Interest Paid	1.1 k	1.5 k

Report incorrect company information

Source: SEC Filings

Report incorrect company information

View Tenax Therapeutics profile

Competitors

Health - Public

Health - Public

Acceleron Pharma

Health - Public

Evelo Biosciences

Health - Private

Compare competitors